{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Solanki P"],"funding":["National Health and Medical Research Council"],"pagination":["e062406"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9664285"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(11)"],"pubmed_abstract":["<h4>Objectives</h4>Primary aldosteronism (PA), the most common endocrine cause of hypertension, is associated with a higher risk of cardiovascular disease (CVD) than blood pressure (BP)-matched essential hypertension (EH). We aimed to compare the calculated risks of CVD in patients who had hypertension with PA or EH using CVD risk calculators, hypothesising that they will fail to recognise the increased CVD risk in PA.<h4>Design</h4>Cross-sectional analysis.<h4>Setting</h4>An endocrine hypertension service in Victoria, Australia.<h4>Participants</h4>Patients who had hypertension without CVD referred for the investigation of hypertension.<h4>Outcome measures</h4>Calculated 5-year or 10-year CVD risk as predicted by the National Vascular Disease Prevention Alliance (NVDPA) algorithm, Framing"],"journal":["BMJ open"],"pubmed_title":["Risky business: a single-centre cross-sectional analysis of calculated cardiovascular risk in patients with primary aldosteronism and essential hypertension."],"pmcid":["PMC9664285"],"funding_grant_id":["Investigator Grant APP1194576"],"pubmed_authors":["Fuller PJ","Solanki P","Gwini SM","Yang J","Shen J","Libianto R","Young MJ","Gabb G"],"additional_accession":[]},"is_claimable":false,"name":"Risky business: a single-centre cross-sectional analysis of calculated cardiovascular risk in patients with primary aldosteronism and essential hypertension.","description":"<h4>Objectives</h4>Primary aldosteronism (PA), the most common endocrine cause of hypertension, is associated with a higher risk of cardiovascular disease (CVD) than blood pressure (BP)-matched essential hypertension (EH). We aimed to compare the calculated risks of CVD in patients who had hypertension with PA or EH using CVD risk calculators, hypothesising that they will fail to recognise the increased CVD risk in PA.<h4>Design</h4>Cross-sectional analysis.<h4>Setting</h4>An endocrine hypertension service in Victoria, Australia.<h4>Participants</h4>Patients who had hypertension without CVD referred for the investigation of hypertension.<h4>Outcome measures</h4>Calculated 5-year or 10-year CVD risk as predicted by the National Vascular Disease Prevention Alliance (NVDPA) algorithm, Framing","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-25T23:34:01.131Z","creation":"2025-04-06T09:22:37.46Z"},"accession":"S-EPMC9664285","cross_references":{"pubmed":["36375972"],"doi":["10.1136/bmjopen-2022-062406"]}}